Choosing the Best AAV Vectors for Safer, More Potent, and Reliable Therapeutic Performance

Choosing the Best AAV Vectors for Safer, More Potent, and Reliable Therapeutic Performance ...

Gene therapy addresses the genetic defect by correcting the mutation using gene-editing tools deployed via delivery vehicles. Over the previous decades, recombinant viral vectors, such as lentiviruses or adenoassociated viruses (AAVs), have been successful as vehicles for gene therapy in clinical trials. However, the complexity of the viral vector structure, mechanisms of viral-host interactions, optimal dosages, and the reported adverse effects have pave the way to enhance existing vectors and pioneer novel approaches to deliver the next-

Dr. Arun Srivastava and Dr. David Schaffer will talk about advances in viral vector development and research that help provide reliable, safer, and potent treatments for blood disorders. Moreover, we will learn more about how AAV vectors are enhancing their delivery ability to many organs with the ability to dodge immune response.

Following the presentation, there was a live Q&A session, which offered the opportunity to ask questions to our expert panelists.

With the help of:

You may also like: